Abstract
We report two novel mutations in the splice sites of BRCA1 exon 5: IVS5+3A>G, a Belgian founder mutation, and IVS3−6T>G, identified in one family with a strong family history of breast cancer. Real-time RT–PCR showed that IVS3−6T>G leads to a fivefold increase of the BRCA1-Δex5 (isoform with an in frame skip of exon 5) ratio to the total BRCA1 expression level. IVS5+3A>G results in a 10-fold increase of the BRCA1-Δ22ntex5 ratio (isoform with an out of frame skip of the last 22 nucleotides of exon 5) and a twofold increase of the BRCA1-Δex5 ratio. These altered ratios are most likely to result from increased expression of the alternative transcripts, although we cannot completely rule out a small decrease of the total BRCA1 expression level due to highly variable BRCA1 levels in cultured cell lines. In order to explore the functional significance of the isoforms, we evaluated their prevalence in normal tissues and cancer cell lines. The BRCA1-Δ22ntex5 ratio was significantly higher in an ovarian cancer cell line compared to normal ovarian tissue. Our findings suggest that revealing the defects caused by some splice mutations requires accurate quantitative methods. We hypothesize that disruption of alternative transcript ratios of BRCA1 may be a dominant mechanism affecting predisposition to hereditary breast and/or ovarian cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abel KJ, Xu J, Yin GY, Lyons RH, Meisler MH, Weber BL . 1995 Hum. Mol. Genet. 4: 2265–2273
Berget SM . 1995 J. Biol. Chem. 270: 2411–2414
Claes K. Machackova E, De Vos M, Poppe B, De Paepe A, Messiaen L . 1999 Dis. Markers 15: 69–73
Easton DF, Bishop DT, Ford D, Crockford GP . 1993 Am. J. Hum. Genet. 52: 678–701
Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM . 2001a Oncogene 20: 77–87
Fan S, Yuan Rq RQ, Ma YX, Meng Q, Goldberg ID, Rosen EM . 2001b Oncogene 20: 8215–8235
Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC . 1999 Proc. Natl. Acad. Sci. USA 96: 9689–9694
Gudas JM, Li T, Nguyen H, Jensen D, Rauscher III FJ, Cowan KH . 1996 Cell. Growth Differ. 7: 717–723
Kudoh T, Ishidate T, Moriyama M, Toyoshima K, Akiyama T . 1995 Proc. Natl. Acad. Sci. USA 92: 4517–4521
Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA . 1995 Nat. Genet. 11: 17–26
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholanni Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barret JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH . 1994 Science 266: 66–71
Ohno K, Brengman JM, Felice KJ, Cornblath DR, Engel AG . 1999 Am. J. Hum. Genet. 65: 635–644
Pummi K, Yla-Outinen H, Peltonen J . 2000 Arch. Dermatol. Res. 292: 422–424
Shapiro MB, Senapathy P . 1987 Nuc. Acids Res. 15: 7155–7174
Singh R, Valcarcel J, Green MR . 1995 Science 268: 1173–1176
Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, Shay JW, Minna JD, Gazdar AF . 1998 Cancer Res. 58: 3237–3242
Vandenbroucke I, Vandesompele J, De Paepe A, Messiaen L . 2001 Nucl. Acids Res. 29: E68–E68
Vandesompele et al . 2002 In press
Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW, Berchuck A, Iglehart JD, Futreal PA, Marks JR . 1996 Cell. Growth Differ. 7: 711–715
Welcsh PL, King MC . 2001 Hum. Mol. Genet. 10: 705–713
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G . 1995 Nature 378: 789–792
Yan H, Dobbie Z, Gruber SB, Markowitz S, Romans K, Giardiello FM, Kinzler KW, Vogelstein B . 2001 Nat. Genet. 30: 25–26
Zamore PD, Patton JG, Green MR . 1992 Nature 355: 609–614
Acknowledgements
K Claes is supported by a research grant of the University of Ghent (GOA 12051397). J Vandesompele obtained a grant from the Flemish Institute for the Promotion of Scientific Technological Research in Industry (IWT). B Poppe is supported by a grant of the Fund for Scientific Research (FWO).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Claes, K., Vandesompele, J., Poppe, B. et al. Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5′ end of the BRCA1 gene. Oncogene 21, 4171–4175 (2002). https://doi.org/10.1038/sj.onc.1205520
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205520
Keywords
This article is cited by
-
Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation
Breast Cancer Research (2016)
-
Functional characterization of BRCA1 gene variants by mini-gene splicing assay
European Journal of Human Genetics (2014)
-
Occurrence of GCH1 gene mutations in a group of Indian dystonia patients
Journal of Neural Transmission (2012)
-
An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition
BMC Medical Genetics (2011)
-
Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes
European Journal of Human Genetics (2011)